Interleukin 15 (IL15) and IL7 are two cytokines essential for T cell development and homeostasis. In order to improve the antitumor activity by Newcastle disease virus (NDV)-modified tumor vaccine, we generated a recombinant NDV co-expressing --
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| INTRODUCTION
Newcastle disease virus (NDV), a member of the genus Avulavirus, has a non-segmented, single-stranded, negative-sense RNA that contains 6 structural genes in the following order (3 0 -5 0 ): nucleoprotein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase (HN) and large polymerase protein (L). 1-3 NDV has been considered as an effective and safe agent for cancer therapy for more than 50 years. 4-6 NDV can selectively replicate in tumor cells, as most of these cells are defective in interfering pathways. 7, 8 Therefore, NDV has been used clinically as an oncolytic agent against many types of cancer. [9] [10] [11] Newcastle disease virus has been used to treat cancer in at least the following three ways: (i) lysing tumor cells directly; 9 (ii) modifying tumor cells as the vaccine to stimulate antitumor immune responses; 12, 13 and as a vector to deliver therapeutic genes. Interleukin 7, one of c-chain cytokines, plays a critical role in lymphocyte development and homeostasis of na€ ıve and memory CD8 + T cells. 16 IL15, another c-chain cytokine, is dedicated to the prolonged maintenance of memory T cell responses, which makes IL15 an attractive candidate for adjuvant immunotherapy. [17] [18] [19] and IL15 support the generation of long-living memory stem T cells, which could differentiate into potent effectors not only able to efficiently target cancer cells, but also capable of persisting and mediating a dynamic cancer immunosurveillance. 20 Therefore, ATV-NDV co-expressing IL7 and IL15 may enhance T cell responses and achieve better therapeutic efficacy against tumors.
Foot-and-mouth disease virus (FMDV) 2A, a self-processing peptide from FMDV, has become a useful approach for the expression of multiple proteins under the control of a single promoter.
Previously, we constructed several recombinant viruses using a reverse genetic platform of nonlytic NDV strain LX. 13 In this study, we generated recombinant LX strain (LX/IL(15+7)) co-expressing IL7
and IL15 through incorporation of a 2A self-processing peptide between the above genes. This recombinant LX/IL(15+7) expressed two heterogenous genes simultaneously. Tumor cells modified with LX/IL(15+7) exhibited increasing preventive and therapeutic effects of cancer both in vitro and in vivo.
| MATERIALS AND METHODS

| Animals
Pathogen-free 6-week-old female C57BL/6 mice were obtained from SLC (Shanghai, China). Animal care and experimental procedures were performed under specific-pathogen-free (SPF) conditions. All animal protocols were approved by the Institutional Laboratory Animal Care and Use Committee at Soochow University. (Table 1) .
| Cells and viruses
The resultant PCR product was digested with AgeI and AvrII and inserted into the AgeI-to-AvrII window of a subclone, nucleotides 2311-8157 in the antigenomic cDNA of NDV strain LX. This subclone encompassed the downstream sequence of the P gene, and the upstream sequence of the M gene. The murine IL7-coding sequence was inserted into nucleotide position 3143 in the antigenomic cDNA because it allowed flanking by a set of GE, IG and GS.
This subclone was digested with Sac II and SpeI, and then assembled into the full-length antigenomic cDNA to result in the full-length clone pLX/IL(15+7).
The recombinant virus LX/IL(15+7) was rescued by cotransfecting BSR T7/5 cells with pLX/IL(15+7) and support plasmids (N, P and L) from ZJ1 strain as previously described. 21 Then, the supernatant from the transfected BSR T7/5 cells was collected and inoculated into allantoic cavities of 10-day-old embryonated SPF eggs.
96 hour later, the allantoic fluid was screened for the virus production by hemagglutination assay (HA) using 0.5% chicken red blood cells. The recombinant viruses were also determined by sequencing for the correct insertion of the heterogenous genes. | 281 measured. Briefly, the fusion proteins in the supernatants were captured using IL15 antibody-coated plates from IL15 DuoSet ELISA, and the amount of fusion protein was determined using the detecting antibody from IL7 DuoSet ELISA.
| Growth kinetics of the virus
| Production of tumor vaccine modified with
Newcastle disease virus were calculated using the formula
| Prophylaxis experiments
, where L is the length (longest dimension) and W is the width (shortest dimension).
| Therapeutic experiments
Mice were inoculated s.c. with 5 9 10 4 B16-F10 cells at the right flank with a 25G5/8 needle. The tumor vaccines were injected s.c.
into the left flank at days 5 and 9 post-tumor inoculation. The tumor sizes were measured daily from day 5 post-challenge.
| In vivo depletion of CD4
+ or CD8 + cells CD4 + or CD8 + cells depletion were performed by i.p. injections of 1 mg GK1.5 (rat anti-mouse CD4 mAb) or 500 lg 53-6.7 (rat anti-mouse CD8 mAb) 2 days before the first immunization in each mouse, and the injections were repeated 7 days later.
| Flow cytometry
Antibodies ( 
| Immunohistochemistry and histopathology
After the mice were killed, tumor tissues were removed aseptically and immediately fixed in 4% formalin at room temperature for 2 days. The fixed tissues were processed through graded concentrations of ethanol and xylene and were then embedded in paraffin wax.
Tissue sections of 4-5 mm were mounted on adhesive glass slides and were stained with HE. Tumor sections were then deparaffinized and treated with 0.08% H 2 O2 for 30 minutes to block endogenous peroxidase. Slides were incubated with rat anti-CD4 (GK1.5; Abcam, Cambridge, MA, USA) or rat anti-CD8 (2.43; Abcam, Cambridge, MA, USA) at 4°C overnight, followed by incubation with HRP-conjugated rabbit anti-rat Ig. Diaminobenzidine was used to develop the staining reaction, and nuclear counterstaining was performed with hematoxylin. Slides were coded and examined by a pathologist who was blinded for the experimental history of the animals.
| Statistical analysis
All data were analyzed by Student t-test and expressed as means AE SEM; data were analyzed using GraphPad Prism 5 software for Windows (GraphPad Software, San Diego, CA, USA), and differences were considered statistically significant when P < .05. The significance levels are marked *P < .05 and **P < .01. 
| Prophylaxis with tumor vaccine modified with LX/IL(15+7)
The in vivo protective effects of LX/IL(15+7)-modified tumor vaccine
were assessed in murine melanoma model. C57BL/6 mice were 
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Lixiang Zhao http://orcid.org/0000-0002-1102-082X R E F E R E N C E S .5 (rat anti-mouse CD4 mAb) or 500 lg 53-6.7 (rat anti-mouse CD8 mAb) 2 d before the first administration of B16-LX/IL(15+7), and the injections were repeated 7 days later. The tumor volumes were monitored daily. The experiments were performed with 6 mice per group. The data shown are representative of the 3 experiments. *P < .05 and **P < .01
